Clinical Trials

Keywords/SWOG Study Number

Area of Research

Accrual Status

Any

Open

Closed

Limit to SWOG Trials

All Trials

SWOG Trials Only

Show only published studies

Study Type

Treatment

Study Chair

Participating Institution

Phase

Cancer Control Subcommittee

Study Sponsor

FDA Registration Trial

Uses PRO Forms

1052 Results

View

Open

Phase

Accrual

69%

SWOG Clinical Trial Number

S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Status Notes

S2308 will open to accrual 08/01/2024, effective 3:00 p.m. EST

Research Committee(s)

Lymphoma

Activated

08-01-2024

ClinicalTrials.gov Registry Number

06337318

Open

Phase

SWOG Clinical Trial Number

MYELOMATCH

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials

Research Committee(s)

myeloMATCH

Leukemia

Activated

05-16-2024

ClinicalTrials.gov Registry Number

NCT05564390

Open

Phase

Accrual

25%

SWOG Clinical Trial Number

MM1YA-S01

A Randomized Phase II Study Comparing Cytarabine +Daunurubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial

Research Committee(s)

myeloMATCH

Leukemia

Activated

05-16-2024

ClinicalTrials.gov Registry Number

NCT05554406

Open

Phase

Accrual

51%

SWOG Clinical Trial Number

S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Research Committee(s)

Gastrointestinal Cancer

Activated

05-06-2024

ClinicalTrials.gov Registry Number

06203600

Open

Phase

Accrual

54%

SWOG Clinical Trial Number

S1900K

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Status Notes

S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.

Research Committee(s)

LungMAP

Activated

12-18-2023

ClinicalTrials.gov Registry Number

NCT06031688

Open

Phase

Accrual

37%

SWOG Clinical Trial Number

S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Status Notes

S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s)

Myeloma

Activated

12-01-2023

ClinicalTrials.gov Registry Number

06022939

Open

Phase

Accrual

43%

SWOG Clinical Trial Number

S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Status Notes

This study is open to patient accrual effective 10/30/23.

Research Committee(s)

Breast Cancer

Symptom Management and Survivorship

Activated

10-30-2023

ClinicalTrials.gov Registry Number

06058377

Open

Phase

Accrual

14%

SWOG Clinical Trial Number

S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Status Notes

Reactivation effective 3/3/26, 12 PM PST.

Research Committee(s)

Genitourinary Cancer

Activated

08-14-2023

ClinicalTrials.gov Registry Number

NCT05806515

Open

Phase

Accrual

69%

SWOG Clinical Trial Number

S2212

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Status Notes

This study is active in SWOG as of July 21, 2023.

Research Committee(s)

Breast Cancer

Activated

07-21-2023

ClinicalTrials.gov Registry Number

NCT05929768

Open

Phase

Accrual

23%

SWOG Clinical Trial Number

S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Status Notes

Effective August 3, 2026, at 12:00 p.m. Pacific Time, Arms 2 and 3 are open to accrual to the randomized portion of the trial.

Effective March 6. 2026, Arm 1 has been permanently closed to accrual.

Research Committee(s)

Lymphoma

Activated

06-30-2023

ClinicalTrials.gov Registry Number

05890352

Open

Phase

Accrual

28%

SWOG Clinical Trial Number

S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance

Status Notes

S2209 is open to patient accrual May 30, 2023, effective 12:00 p.m. Pacific Time.

Research Committee(s)

Myeloma

Activated

05-30-2023

ClinicalTrials.gov Registry Number

05561387

Open

Phase

Accrual

64%

SWOG Clinical Trial Number

S1900G

A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Status Notes

S1900G will open to accrual April 3, 2023, effective 3:00 p.m. EST.

Research Committee(s)

LungMAP

Activated

04-03-2023

ClinicalTrials.gov Registry Number

05642572

Open

Phase

Accrual

86%

SWOG Clinical Trial Number

S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy

Status Notes

This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.

Research Committee(s)

Symptom Management and Survivorship

Activated

03-16-2023

ClinicalTrials.gov Registry Number

05642611

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER

Status Notes

S2302 will permanently closed to accrual effective December 20, 2024, at 12:00 p.m. Pacific Time.

Research Committee(s)

Lung Cancer

Activated

03-06-2023

Closed

12-20-2024

ClinicalTrials.gov Registry Number

05633602

Open

Phase

Accrual

100%

SWOG Clinical Trial Number

EAY191-S3

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors

Status Notes

This study is open to participant enrollment effective 12pm PT on 3/6/2023.

Research Committee(s)

comboMATCH

Immunomolecular Therapeutics

Activated

03-06-2023

ClinicalTrials.gov Registry Number

05554380

Open

Phase

Accrual

62%

SWOG Clinical Trial Number

S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Status Notes

Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time

Research Committee(s)

Lymphoma

Activated

02-23-2023

ClinicalTrials.gov Registry Number

05633615

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)

Status Notes

This study is permanently closed to participant accrual, effective January 15, 2025, at 12:00 p.m. Pacific Time.

Research Committee(s)

Symptom Management and Survivorship

Activated

01-17-2023

Closed

01-15-2025

Open

Phase

Accrual

49%

SWOG Clinical Trial Number

S2101

Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers

Status Notes

Stage II Activation: This study will be reopen to Stage II accrual to both the Melanoma and HNSCC cohorts effective May 1st, 2025, at 3:00 PM ET / 12:00 PM PT.

Research Committee(s)

iMATCH

Head and Neck Cancer

Melanoma

Early Therapeutics & Rare Cancers

Immunomolecular Therapeutics

Activated

10-14-2022

ClinicalTrials.gov Registry Number

NCT 05136196

Closed

Phase

Accrual

18%

SWOG Clinical Trial Number

S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Status Notes

Permanently Closed to Accrual effective 3/1/2026.

Research Committee(s)

Genitourinary Cancer

Activated

09-19-2022

Closed

01-17-2026

ClinicalTrials.gov Registry Number

NCT05411081

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S2108CD

A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy

Status Notes

This study will be permanently closed to new patient accrual, effective November 22, 2024, at 3:00 p.m. Eastern Time.

Research Committee(s)

Cancer Care Delivery

Activated

08-22-2022

ClinicalTrials.gov Registry Number

NCT # 05455606